On the heels of major Pfizer deal, Arvinas snags $55M Series C for protein degradation cancer programs
After inking two major deals with Big Pharmas tackling the increasingly hot path of protein degradation earlier this year, Yale spinout Arvinas has scored a $55 million round of funding to take two of its cancer programs through the clinic.
The cash came in a Series C round led by oncology-focused fund Nextech Invest, which is new to Arvinas’ lineup of financial backers. Other new investors Deerfield Management, Hillhouse Capital and Sirona Capital joined the round, along with a slew of repeats.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
